New drug combo aims to shrink stomach cancer before surgery
NCT ID NCT07493382
First seen Mar 26, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This early-phase trial tests whether adding an experimental immunotherapy drug called Retlirafusp alfa to standard chemotherapy can improve outcomes for people with gastroesophageal junction cancer. About 30 participants will receive the combination before surgery, then some may continue the immunotherapy afterward. The main goal is to see how many patients have no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retlirafusp alfa (an experimental immunotherapy drug) combined with capecitabine and oxaliplatin (chemotherapy)
What this could lead to
If successful, this could point toward a more effective treatment approach for gastroesophageal junction cancer, potentially improving tumor shrinkage before surgery and delaying recurrence.
What could go wrong
This is a very early, small (30 people), single-arm study with no comparison group. The drug combination may cause significant side effects, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.